 SAN FRANCISCO, Oct. 14, 2021 PRNewswire -- Hagens Berman urges Revance Therapeutics, Inc. NASDAQ: RVNC investors to with significant losses to submit your losses now. Visit: Contact An Attorney Now: 844-916-0895 Revance Therapeutics, Inc. RVNC Investigation: Revance Therapeutics plans to compete in the Botulinum toxin market dominated by Allegans BOTOX. 